News
The authorisation comes three months after the MHRA approved Johnson & Johnson’s Lazcluze (lazertinib), which is also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback